Vaccine development for the prevention of urinary tract infections

Current Infectious Disease Reports

Volumn 4, Issue 6, 2002, Pages 509-513

  Hopkins, Walter J ^a   Uehling, David T ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Bladder Epithelial Cell; Prostatitis; Recurrent Urinary Tract Infection; Urethritis; Urinary Tract Infection

Indexed keywords

EID: 0041635424     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-002-0037-8     Document Type: Article

References (23)

1. Ronald AR, Nicolle LE, Stamm E, et al.: Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents 2001, 17:343–348.
2. Gupta K, Sahm DF, Mayfield D, et al.: Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 2001, 33:89–94.
3. Sahm DF, Thornsberry C, Mayfield DC, et al.: Multidrug-resistant urinary tract isolates of Escherichia coli: Prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother 2001, 45:1402–1406.
4. Ogra PL, Faden H, Welliver RC: Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001, 14:430–445.
5. Ruttgers H, Grischke E: Elevation of secretory IgA antibodies in the urinary tract by immunostimulation for the preoperative treatment and post-operative prevention of urinary tract infections. Urol Int 1987, 42:424–426.
6. Grischke EM, Ruttgers H: Treatment of bacterial infections of the female urinary tract by immunization of the patients. Urol Int 1987, 42:338–341.
7. Hopkins WJ, James LJ, Uehling DT, Balish E: Vaginal mucosal and parenteral immunization of mice with bacteria. J Urol 1991, 146:223–226.
8. Uehling DT, Hopkins WJ, James LJ, et al.: Vaginal immunization of monkeys against urinary tract infection with a multi-strain vaccine. J Urol 1994, 151:214–216.
9. Uehling DT, Hopkins WJ, Dahmer LA, et al.: Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection. J Urol 1994, 152:2308–2311.
10. Uehling DT, Hopkins WJ, Balish E, et al.: Vaginal mucosal immunization for recurrent urinary tract infection: Phase II clinical trial. J Urol 1997, 157:2049–2052. Describes phase 2 clinical trials of vaginal suppository immunization with Urovac®.
11. Uehling DT, Hopkins WJ, Beierle LM, et al.: Vaginal immunization for recurrent urinary tract infection: extended phase II clinical trial. J Infect Dis 2001, 183(Suppl 1):S81-S83.
12. Bessler WG, Kleine B, Martinez A, et al.: Biological activity of bacterial surface components: bacterial extracts and defined bacterial cell wall components as immunmodulators. Lung 1990, 168:707–715.
13. Sedelmeier E, Bessler WG: Biological activity of bacterial cell wall components: immunogenicity of the bacterial extract OM-89. Immunopharmacology 1995, 29:29–36.
14. Huber M, Baier W, Serr A, et al.: Immunogenicity of an E. coli extract after oral or intraperitoneal administration: induction of antibodies against pathogenic bacterial strains. Int J Immunopharmacol 2000, 22:57–68.
15. Huber M, Krauter K, Winkelmann G, et al.: Immunostimulation by bacterial components: II. Efficacy studies and metaanalysis of the bacterial extract OM-89. Int J Immunopharmacol 2000, 22:1103–1111. Summary of Uro-Vaxom® animal and human studies and metaanalysis of clinical trials.
16. Wybran J, Libin M, Schandene L: Enhancement of cytokine production and natural killer activity by an Escherichia coli extract. Immunopharmacol Immunotoxicol 1989, 11:17–32.
17. Koukalova D, Reif R, Hajek V, et al.: Urvakol vaccine in immunomodulation of recurrent urinary tract infections. Bratisl Lek Listy 1999, 100:246–251.
18. Nenkov P: Overview on the clinical studies with Urostim immunostimulator against urogenital infections. Adv Exp Med Biol 2000, 485:325–329.
19. Roberts JA, Hardaway K, Kaack B: Prevention of pyelonephritis by immunization with p-fimbriae. J Urol 1984, 131:602–607.
20. Connell H, Agace W, Klemm P, et al.: Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci U S A 1996, 93:9827–9832.
21. Langermann S, Ballou WR: Vaccination using the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections. J Infect Dis 2001, 183(Suppl 1):S84-S86.
22. Langermann S, Palaszynski S, Barnhart M, et al.: Prevention of mucosal Escherichia coli infection by FimH adhesin-based systemic vaccination. Science 1997, 276:607–611. Contains studies of parenteral immunization of mice with type 1 adhesin of E. coli.
23. Langermann S, Mollby R, Burlein J, et al.: Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 2000, 181:774–778.